Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 7, 2010, Pages 649-652

  Dharmasaroja, Pornpatr A ^a   Sae Lim, Suvaraporn ^b  

^a THAMMASAT UNIVERSITY   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

antiplatelet; aspirin; urine dehydrothromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CREATININE;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DYSPEPSIA; ENTERIC COATED TABLET; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION; URINALYSIS;

ADULT; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; SEX FACTORS; TABLETS, ENTERIC-COATED; THROMBOXANE B2; TIME FACTORS;

EID: 77958196642     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833cea2c     Document Type: Article

References (20)

1. Sztriha LK, Sas K, Vessei L. Aspirin resistance in stroke: 2004. J Neurol Sci 2005; 229-230:163-169. (Pubitemid 40341581)
2. Pamukcu B. A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis 2007; 23:213-222. (Pubitemid 46564122)
3. Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systemic review and meta-analysis. Arch Intern Med 2007; 167:1593-1599.
4. Krasopoulos G, Brister SJ, Beattie WS, Elliot RF, Buchanan MR. Aspirin 'resistance' and risk of cardiovascular morbidity: systemic review and metaanalysis. BMJ 2008; 336:195-198. (Pubitemid 351212675)
5. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008; 19:119-124. (Pubitemid 351302375)
6. Lordkipanidze M, Pharand C, Scheampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28:1702-1708. (Pubitemid 47227104)
7. Eikelboom JW, Hirsh J, Weitz JL, Johnston M, Yi Q, Yusuf S. Aspirin resistance and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk of cardiovascular outcomes. Circulation 2002; 105:1650-1655. (Pubitemid 34298607)
8. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004; 328:477-479. (Pubitemid 38293602)
9. Fritsma GA, Ens GE, Alvord MA, Carroll AA, Jensen R. Monitoring the antiplatelet action of aspirin. JAAPA 2001; 14:57-62.
10. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness and side effects. Chest 2001; 119 (Suppl):39S-63S. (Pubitemid 32154194)
11. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118:723-727. (Pubitemid 40897657)
12. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study. Circulation 2007; 115:3156-3164. (Pubitemid 47012230)
13. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35:175-178. (Pubitemid 38057615)
14. Bruno A, McConnell JP, Mansbach HM, Cohen SN, Tietjen GE, Bang NU. Aspirin and urinary 11-dehydrothromboxane B2 in African American stroke patients. Stroke 2002; 33:57-60. (Pubitemid 34052185)
15. Karon BS, Wockenfus A, Scott R, Hartman SJ, McConnell JP, Santrach PJ, et al. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. Clin Chem 2008; 54: 1060-1065. (Pubitemid 351793414)
16. Hecken AV, Juliano ML, Depre M, De Lepeleire I, Arnout J, Dynder A, et al. Effects of enteric-coated, low-dose aspirin on parameters of platelet function. Aliment Pharmacol Ther 2002; 16:1683-1688.
17. Shen H, Herzog W, Drolet MA, Pakyz R, Newcomer S, Sack P, et al. Aspirin resistance in healthy drug-naïve men versus women (from the hereditary and phenotype intervention heart study). Am J Cardiol 2009; 104:606-612.
18. Qayyum R, Becker DM, Yanek LR, Moy TF, Becker LC, Faraday N, et al. Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol 2008; 101:1359-1363.
19. Linneman B, Prochnow S, Mani H, Schwonberg J, Lindhoff-Last E. Variability of nonresponse to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. Ann Hematol 2009; 88:979-988.
20. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108:37-42. (Pubitemid 36197660)